hydrocortisone acetate pramoxine HCl
RxNorm 1234506· HYDROCORTISONE ACETATE, PRAMOXINE HCL· TOPICAL
Bryant Ranch Prepack
Indications and usage
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and administration
DOSAGE AND ADMINISTRATION Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Pregnancy
Pregnancy: Teratogenic Effects: Pregnancy Category C – Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Nursing mothers
Nursing Mothers - It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities NOT likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- asthenia1
- condition aggravated1
- erythema1
- fatigue1
- feeling abnormal1
- pain of skin1
- prostatitis1
- skin discomfort1
- skin exfoliation1
- surgery1
Adverse reactions (label)
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria
KR · 한국Products in Korea (148)
- 오토스포린귀약(주)글락소스미스클라인
- 더모케어로오숀0.5%(히드로코르티손)(주)나노팜
- 더모케어로오숀0.5%(히드로코르티손)(주)나노팜
- 더모케어로오숀0.5%(히드로코르티손)(주)나노팜
- 더모케어로오숀2.5%(히드로코르티손)(주)나노팜
- 더모케어로오숀2.5%(히드로코르티손)(주)나노팜
- 하이톤로오숀1.0%(하이드로코르티손)(주)나노팜
- 하이톤로오숀2.5%(하이드로코르티손)(주)나노팜
- 엠엘이에이치씨1%크림(히드로코르티손)(주)네오팜
- 엠엘이에이치씨크림1%(히드로코르티손)(주)네오팜
- 엠엘이에이치씨크림1%(히드로코르티손)(수출용)(주)네오팜
- 엠엘이에이치씨크림1%(히드로코르티손)(수출용)(주)네오팜
- 에이크리손액(히드로코르티손)(주)대웅
- 코디케어로션2.5%(히드로코르티손)(주)동구바이오제약
- 코디케어로션2.5%(히드로코르티손)(주)동구바이오제약
- 코디케어로션2.5%(히드로코르티손)(주)동구바이오제약
- 코디케어로션2.5%(히드로코르티손)(주)동구바이오제약
- 마이케어로션1%(히드로코르티손)(주)마더스제약
- 마이케어로션1%(히드로코르티손)(주)마더스제약
- 마이케어로션1%(히드로코르티손)(주)마더스제약
View more: Full FDA label on DailyMed →Label effective 20251024